On Thursday, Goldman Sachs (NYSE:GS) revised its stance on Novartis , downgrading the stock from Buy to Neutral and adjusting the price target to CHF 103 from CHF 105. The decision follows a period of solid share price performance and earnings upgrades for the pharmaceutical giant.
The downgrade is attributed to the stock's recent 11% increase, which Goldman Sachs believes is partly due to general market trends. Other factors contributing to the stock's performance include consistent positive earnings momentum, with Novartis raising its FY24E guidance in both the first and second quarters. Additionally, the company has doubled its share buyback activity since mid-June 2024, purchasing around 400,000 shares compared to the previous 200,000.
Goldman Sachs noted that while Novartis has achieved its major news event of the year with the Phase 3 ASC4FIRST readout for Scemblix in 1L CML, the firm sees limited near-term catalysts that could drive the stock's value further. This assessment is based on Goldman Sachs' criteria for evaluating their Large Pharma universe, which includes innovation momentum, earnings momentum, and valuation.
The analyst's commentary highlighted that the consensus has caught up to their estimates, suggesting that the market has already accounted for the recent positive developments in Novartis' earnings. As a result, Goldman Sachs anticipates fewer opportunities for significant stock appreciation in the immediate future.
In other recent news, Novartis AG (SIX:NOVN) has posted strong growth in its Q2 2024 earnings report, with an 11% increase in sales and a 19% rise in core operating income.
The pharmaceutical company has upgraded its full-year 2024 guidance, reflecting high single-digit to low double-digit sales growth and mid- to high-teens growth in core operating income. Key contributors to this growth include products like Kesimpta, Kisqali, and Cosentyx.
The company also reported a significant increase in innovative medicines company revenue, from $35 billion to $50 billion. Despite challenges such as currency fluctuations and International Reference Pricing (IRA), Novartis remains optimistic about its future growth.
The company's CEO, Vas Narasimhan, has discussed plans to increase the number of Pluvicto cycles per patient and expand into other indications. Novartis is also planning multiple FDA submissions with a focus on oncology and the RLT platform.
InvestingPro Insights
In light of the recent downgrade by Goldman Sachs, a closer look at Novartis' financial metrics through InvestingPro reveals a company with a robust financial performance. Novartis boasts a market capitalization of $241.45 billion, reflecting its significant presence in the pharmaceutical industry. The company has demonstrated a strong revenue growth of 9.7% in the last twelve months as of Q2 2024, underlining its ability to expand its sales amidst a competitive landscape.
An impressive gross profit margin of 75.55% in the same period indicates Novartis' efficiency in managing its production costs and maintaining profitability. Furthermore, the company's return on assets stands at 15.52%, showcasing its effectiveness in utilizing its assets to generate earnings. Investors also enjoy a dividend yield of 2.04%, coupled with a dividend growth of 6.88%, pointing to Novartis' commitment to delivering shareholder value.
For those looking to delve deeper, InvestingPro offers additional insights with more InvestingPro Tips to help investors understand the potential of Novartis shares in the context of the broader market. With the next earnings date on October 29, 2024, investors will be keen to see if the company can maintain its momentum and possibly provide the catalysts Goldman Sachs finds currently lacking.
It's worth noting that the InvestingPro Fair Value is set at $125.3 USD, suggesting that there may still be room for growth despite the recent price surge and Goldman Sachs' conservative outlook. For a comprehensive analysis, investors can explore the full suite of InvestingPro Tips, which currently includes numerous additional tips for a well-rounded investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.